Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F3SYP
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,616
Award facts
- Contract value 100% obligated
- $37,615.78 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $37,615.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) on January 6, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors, with completion scheduled for January 7, 2026. This is a non-set-aside competitive award fulfilled by the prime contractor's Corporate Office division located in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 global pharmaceutical support vehicle running through December 2031 that enables the supply of a comprehensive range of medications, vaccines, medical devices, and specialized healthcare commodities to military treatment facilities and veteran healthcare systems worldwide.
This delivery order represents a typical transaction within AmerisourceBergen's extensive federal pharmaceutical supply portfolio, which demonstrates the company's consistent capability to fulfill government medical procurement requirements through open competition. Repatha (evolocumab) is a PCSK9 inhibitor used for cholesterol management and cardiovascular disease prevention, reflecting the DLA's procurement of specialty pharmaceutical products critical to military healthcare operations. The short completion timeline indicates an urgent supply need, and the award to this established federal vendor underscores its role as a primary pharmaceutical distributor for the Department of Defense medical supply chain.
Quick answers
Who was awarded contract SPE2DR26F3SYP?
SPE2DR26F3SYP was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26F3SYP worth?
The government has obligated $37,616 on SPE2DR26F3SYP.
Is contract SPE2DR26F3SYP an order under another contract?
Yes. SPE2DR26F3SYP is a delivery order under SPE2DR25D2104, an indefinite delivery contract.
Was contract SPE2DR26F3SYP competed?
The extent of competition for SPE2DR26F3SYP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award